Regencell Bioscience (NASDAQ:RGC) Stock Jumps 7.6% – Should You Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares traded up 7.6% on Monday. The stock traded as high as $10.20 and last traded at $10.32. Approximately 165,426 shares changed hands during mid-day trading, a decline of 44% from the average session volume of 294,478 shares. The stock had previously closed at $9.59.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on RGC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, September 21st. Wall Street Zen downgraded shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Regencell Bioscience Stock Up 4.0%

The business has a 50 day moving average price of $6.45 and a 200-day moving average price of $13.83.

Regencell Bioscience (NASDAQ:RGC) last announced its earnings results on Wednesday, October 7th. The company reported ($0.01) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Regencell Bioscience stock. Bank of America Corp DE increased its position in Regencell Bioscience Holdings Limited (NASDAQ:RGC) by 59,113.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,172 shares of the company’s stock after purchasing an additional 17,143 shares during the quarter. Bank of America Corp DE’s holdings in Regencell Bioscience were worth $437,000 as of its most recent filing with the Securities and Exchange Commission. 0.13% of the stock is currently owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited is a Hong Kong-based biotechnology company focused on developing traditional Chinese medicine (TCM) formulations for neurological and neurocognitive disorders. Its research has primarily targeted attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), conditions for which the company is exploring TCM-based therapeutic approaches.

The company’s development activities center on proprietary herbal formulations and related treatment protocols.